|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Anxiety disorder, generalized |
|
Depression |
| |
|
|
SIDE EFFECTS:
|
|
palpitation |
|
tachycardia |
|
CNS effects |
|
abnormal thinking |
|
agitation |
|
confusion |
|
depersonalization |
|
emotional lability |
|
tinnitus |
|
Dyspnea |
|
edema |
|
itching or skin rash |
|
mania or hypomania |
|
menstrual changes |
|
orthostatic hypotension |
|
seizures |
|
trismus |
|
urinary effects, including impaired urination |
|
urinary frequency |
|
urinary incontinence |
|
urinary retention |
|
Abnormal dreams |
|
anorexia |
|
anxiety or nervousness |
|
asthenia |
|
chills |
|
constipation |
|
diarrhea |
|
dizziness |
|
dryness of mouth |
|
dyspepsia |
|
increased sweating |
|
insomnia |
|
nausea |
|
paresthesia |
|
rhinitis |
|
somnolence |
|
stomach pain or gas |
|
tremor |
|
vomiting |
|
weight loss |
|
yawning |
|
Hypertonia |
|
taste perversion |
|
Asthenia |
|
changes in dreaming |
|
dizziness |
|
dryness of mouth |
|
headache |
|
increased sweating |
|
insomnia |
|
nausea |
|
Headache |
|
hypertension |
|
sexual dysfunction, including anorgasmia |
|
decreased libido |
|
delayed ejaculation |
|
impotence |
|
vision disturbances, including abnormal accommodation |
|
blurred vision |
|
Cardiovascular effects, other, including chest pain |
|
nervousness |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Blood pressure problems |
|
>> Cardiac disease |
|
>> Hepatic function impairment |
|
>> Mania |
|
Neurological impairment, including mental retardation |
|
>> Renal function impairment |
|
Seizures |
|
Sensitivity to venlafaxine |
|
Weight loss |
|
|
ADULT DOSE:
|
|
Antidepressant-
Oral, initially 75 mg (base) a day in a single dose, taken with food, in the morning or evening .
Some patients may require an initial dosage of 37.5 mg (base) a day for four to seven days in order to adjust to the medication .
The dosage may be increased, as needed and tolerated, in increments of 75 mg a day at intervals of at least four days .
Anxiety-
Oral, initially 75 mg (base) a day in a single dose, taken with food, in the morning or evening .
Some patients may require an initial dosage of 37.5 mg (base) a day for four to seven days in order to adjust to the medication .
The dosage may be increased, as needed and tolerated, in increments of 75 mg a day at intervals of at least four days .
Note: Patients with moderate hepatic function impairment should receive an initial dosage reduction of 50% .
Patients with renal function impairment should receive an initial dosage reduction of 25 to 50% .
The total daily dose for patients undergoing hemodialysis should be reduced by 50% and the dose should be administered after completion of the dialysis session . |
|
MAXIMUM ADULT DOSE:
|
|
225 mg per day .
The maximum recommended dosage of 225 mg per day reflects experience in moderately depressed outpatients .
However, severely depressed inpatients in a study using the prompt-release dosage form responded to dosages up to 375 mg per day .
There is little experience with the extended-release dosage form at dosages above 225 mg per day, and whether severely depressed patients will respond to higher dosages has not been established .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Antidepressant-
Oral, initially 75 mg (base) a day in a single dose, taken with food, in the morning or evening .
Some patients may require an initial dosage of 37.5 mg (base) a day for four to seven days in order to adjust to the medication .
The dosage may be increased, as needed and tolerated, in increments of 75 mg a day at intervals of at least four days .
Anxiety-
Oral, initially 75 mg (base) a day in a single dose, taken with food, in the morning or evening .
Some patients may require an initial dosage of 37.5 mg (base) a day for four to seven days in order to adjust to the medication .
The dosage may be increased, as needed and tolerated, in increments of 75 mg a day at intervals of at least four days .
Note: Patients with moderate hepatic function impairment should receive an initial dosage reduction of 50% .
Patients with renal function impairment should receive an initial dosage reduction of 25 to 50% .
The total daily dose for patients undergoing hemodialysis should be reduced by 50% and the dose should be administered after completion of the dialysis session . |
|
|
|
|
|